melphalan

Summary

Summary: An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.

Top Publications

  1. ncbi Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy--European Blood and Marrow Transplantation Mucositis Advisory Group
    Nicole Blijlevens
    Department of Hematology, University Medical Center St Radboud, PO Box 9101 6500 HB Nijmegen, The Netherlands
    J Clin Oncol 26:1519-25. 2008
  2. ncbi Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial
    Antonio Palumbo
    Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero Universitaria A O U S Giovanni Battista, Torino, Italy
    J Clin Oncol 28:5101-9. 2010
  3. pmc Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients
    Maria Teresa Cibeira
    Amyloid Treatment and Research Program, Department of Medicine, Boston University School of Medicine, Boston, MA 02118, USA
    Blood 118:4346-52. 2011
  4. ncbi Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model
    Lori A Hazlehurst
    Department of Interdisciplinary Oncology, H Lee Moffitt Cancer Center and Research Institute, at the University of South Florida, 12902 Magnolia Drive, Tampa, FL 33612, USA
    Cancer Res 63:7900-6. 2003
  5. ncbi A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma
    Henk M Lokhorst
    University Medical Center, Utrecht, The Netherlands
    Blood 115:1113-20. 2010
  6. ncbi Intravitreal melphalan for refractory or recurrent vitreous seeding from retinoblastoma
    Fariba Ghassemi
    Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Islamic Republic of Iran
    Arch Ophthalmol 130:1268-71. 2012
  7. ncbi Inhibition of hypoxia-inducible factor-1 function enhances the sensitivity of multiple myeloma cells to melphalan
    Yongzhen Hu
    Department of Hematology and Oncology, University of Yamanashi, Yamanashi, Japan
    Mol Cancer Ther 8:2329-38. 2009
  8. ncbi Experimental study enhancing the chemosensitivity of multiple myeloma to melphalan by using a tissue-specific APE1-silencing RNA expression vector
    Zhen Zhou Yang
    Department of Hematology, Xinqiao Hospital, Third Military Medical University, Chongqing, PR China
    Clin Lymphoma Myeloma 7:296-304. 2007
  9. ncbi Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myelom
    Maria Victoria Mateos
    University Hospital of Salamanca, Salamanca, Spain
    Lancet Oncol 11:934-41. 2010
  10. ncbi A comparison of the cytogenetic alterations and global DNA hypomethylation induced by the benzene metabolite, hydroquinone, with those induced by melphalan and etoposide
    Z Ji
    Division of Environmental Health Sciences, School of Public Health, University of California at Berkeley, Berkeley, CA 94720 7360, USA
    Leukemia 24:986-91. 2010

Detail Information

Publications341 found, 100 shown here

  1. ncbi Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy--European Blood and Marrow Transplantation Mucositis Advisory Group
    Nicole Blijlevens
    Department of Hematology, University Medical Center St Radboud, PO Box 9101 6500 HB Nijmegen, The Netherlands
    J Clin Oncol 26:1519-25. 2008
    ....
  2. ncbi Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial
    Antonio Palumbo
    Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero Universitaria A O U S Giovanni Battista, Torino, Italy
    J Clin Oncol 28:5101-9. 2010
    The combination of bortezomib-melphalan-prednisone (VMP) is a new standard of care for newly diagnosed multiple myeloma...
  3. pmc Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients
    Maria Teresa Cibeira
    Amyloid Treatment and Research Program, Department of Medicine, Boston University School of Medicine, Boston, MA 02118, USA
    Blood 118:4346-52. 2011
    Previous studies have suggested that, in patients with AL amyloidosis treated with high-dose melphalan and autologous stem-cell transplantation (HDM/SCT), the greatest benefit is seen in those patients achieving a hematologic complete ..
  4. ncbi Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model
    Lori A Hazlehurst
    Department of Interdisciplinary Oncology, H Lee Moffitt Cancer Center and Research Institute, at the University of South Florida, 12902 Magnolia Drive, Tampa, FL 33612, USA
    Cancer Res 63:7900-6. 2003
    ..To examine mechanisms of cellular resistance to melphalan, we compared genotypic and phenotypic profiles of acquired and de novo melphalan resistance in an isogenic human ..
  5. ncbi A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma
    Henk M Lokhorst
    University Medical Center, Utrecht, The Netherlands
    Blood 115:1113-20. 2010
    ..After induction therapy and stem cell mobilization, patients were to receive high-dose melphalan, 200 mg/m(2), followed by maintenance with alpha-interferon (arm A) or thalidomide 50 mg daily (arm B)...
  6. ncbi Intravitreal melphalan for refractory or recurrent vitreous seeding from retinoblastoma
    Fariba Ghassemi
    Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Islamic Republic of Iran
    Arch Ophthalmol 130:1268-71. 2012
    ..To evaluate the efficacy and complications of intravitreal chemotherapy for viable vitreous seeding from retinoblastoma...
  7. ncbi Inhibition of hypoxia-inducible factor-1 function enhances the sensitivity of multiple myeloma cells to melphalan
    Yongzhen Hu
    Department of Hematology and Oncology, University of Yamanashi, Yamanashi, Japan
    Mol Cancer Ther 8:2329-38. 2009
    ..by echinomycin, a specific HIF-1 inhibitor, or a siRNA against HIF-1alpha resulted in enhanced sensitivity to melphalan in myeloma cells...
  8. ncbi Experimental study enhancing the chemosensitivity of multiple myeloma to melphalan by using a tissue-specific APE1-silencing RNA expression vector
    Zhen Zhou Yang
    Department of Hematology, Xinqiao Hospital, Third Military Medical University, Chongqing, PR China
    Clin Lymphoma Myeloma 7:296-304. 2007
    ....
  9. ncbi Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myelom
    Maria Victoria Mateos
    University Hospital of Salamanca, Salamanca, Spain
    Lancet Oncol 11:934-41. 2010
    Bortezomib plus melphalan and prednisone (VMP) is significantly better than melphalan plus prednisone alone for elderly patients with untreated multiple myeloma; however, toxic effects are high...
  10. ncbi A comparison of the cytogenetic alterations and global DNA hypomethylation induced by the benzene metabolite, hydroquinone, with those induced by melphalan and etoposide
    Z Ji
    Division of Environmental Health Sciences, School of Public Health, University of California at Berkeley, Berkeley, CA 94720 7360, USA
    Leukemia 24:986-91. 2010
    ..with HQ for 48 h, and compared the HQ-induced alterations with those induced by two well-known leukemogens, melphalan, an alkylating agent, and etoposide, a DNA topoisomerase II inhibitor...
  11. ncbi Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network
    Antonio Palumbo
    Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliera S Giovanni Battista, Torino, Italy
    J Clin Oncol 25:4459-65. 2007
    Lenalidomide has shown significant antimyeloma activity in clinical studies. Oral melphalan, prednisone, and thalidomide have been regarded as the standard of care in elderly multiple myeloma patients...
  12. ncbi Melphalan and its role in the management of patients with multiple myeloma
    Patrizia Falco
    Azienda Ospedaliera San Giovanni Battista, Divisione di Ematologia dell Universita di Torino, Torino, Italy
    Expert Rev Anticancer Ther 7:945-57. 2007
    b>Melphalan is an alkylating agent approved for the treatment of multiple myeloma and ovarian cancer...
  13. ncbi Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
    Jesus F San Miguel
    Hospital Universitario Salamanca, CIC, IBMCC USAL CSIC, Salamanca, Spain
    N Engl J Med 359:906-17. 2008
    The standard treatment for patients with multiple myeloma who are not candidates for high-dose therapy is melphalan and prednisone...
  14. pmc Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial
    Meletios A Dimopoulos
    University of Athens School of Medicine, Alexandra Hospital, Athens, Greece
    Haematologica 98:784-8. 2013
    ..diagnosed multiple myeloma aged 65 years or over were randomized 1:1:1 to nine 4-week cycles of lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance; or lenalidomide, melphalan, and prednisone, or melphalan ..
  15. ncbi Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study
    Pierre Wijermans
    Haga Hospital, Leyweg 275, The Hague, The Netherlands
    J Clin Oncol 28:3160-6. 2010
    For several decades, the treatment of elderly patients with multiple myeloma (MM) has consisted of melphalan and prednisone (MP)...
  16. ncbi Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone
    Jean Luc Harousseau
    Centre Rene Gauducheau, Nantes St Herblain, France
    Blood 116:3743-50. 2010
    The phase 3 Velcade as Initial Standard Therapy in Multiple Myeloma: Assessment with Melphalan and Prednisone study in newly diagnosed multiple myeloma patients ineligible for high-dose therapy demonstrated that bortezomib-melphalan-..
  17. pmc The FA/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells
    Qing Chen
    Department of Interdisciplinary Oncology and Experimental Therapeutics Program, Biostatistics Core Facility, H Lee Moffitt Cancer Center and Research Institute at University of South Florida, 12902 Magnolia Dr, Tampa, FL 33612, USA
    Blood 106:698-705. 2005
    b>Melphalan, a DNA cross-linker, is one of the most widely used and effective drugs in the treatment of multiple myeloma (MM)...
  18. ncbi Long-term results of tumor necrosis factor alpha- and melphalan-based isolated limb perfusion in locally advanced extremity soft tissue sarcomas
    Jan P Deroose
    Daniel den Hoed Cancer Center, Erasmus MC, Rotterdam, The Netherlands
    J Clin Oncol 29:4036-44. 2011
    ..or facilitate function-preserving surgery can be achieved by tumor necrosis factor α (TNF) -based and melphalan-based isolated limb perfusion (TM-ILP)...
  19. ncbi Isolated limb perfusion with the tumor-targeting human monoclonal antibody-cytokine fusion protein L19-TNF plus melphalan and mild hyperthermia in patients with locally advanced extremity melanoma
    Francesco Papadia
    Department of Surgery DI C M I, Genoa University, Genoa, Italy
    J Surg Oncol 107:173-9. 2013
    ..This exploratory trial evaluates safety and clinical activity of L19-TNF plus melphalan-containing isolated limb perfusion (ILP) in extremity melanoma patients.
  20. ncbi The novel, orally bioavailable HSP90 inhibitor NVP-HSP990 induces cell cycle arrest and apoptosis in multiple myeloma cells and acts synergistically with melphalan by increased cleavage of caspases
    Britta Lamottke
    Department of Hematology and Oncology, Charite Universitaetsmedizin Berlin, Berlin, Germany
    Eur J Haematol 88:406-15. 2012
    ..Exposure of MM cells to a combination of NVP-HSP990 and either melphalan or histone deacetylase (HDAC) inhibitors caused synergistic inhibition of viability, increased induction of ..
  21. ncbi Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma
    Massimo Offidani
    Clinica di Ematologia, Azienda Ospedaliero Universitaria Ospedali Riuniti, Ancona, Italy
    Leuk Lymphoma 53:1722-7. 2012
    The combination of melphalan, prednisone and thalidomide (MPT) has demonstrated efficacy and acceptable toxicity in newly diagnosed and relapsed/refractory patients with multiple myeloma (MM)...
  22. ncbi Pharmacokinetic analysis of melphalan after superselective ophthalmic artery infusion in preclinical models and retinoblastoma patients
    Paula Schaiquevich
    CONICET, Clinical Pharmacokinetics Unit, Hospital de Pediatria JP Garrahan, and Department of Pharmacology, Faculty of Pharmacy and Biochemistry, University of Buenos Aires, Buenos Aires, Argentina
    Invest Ophthalmol Vis Sci 53:4205-12. 2012
    To characterize melphalan pharmacokinetics after superselective ophthalmic artery infusion (SSOAI) in animals and children with retinoblastoma.
  23. ncbi Phase I study of continuous-infusion L-S,R-buthionine sulfoximine with intravenous melphalan
    H H Bailey
    Department of Medicine, University of Wisconsin Comprehensive Cancer Center, Madison 53792, USA
    J Natl Cancer Inst 89:1789-96. 1997
    ..We performed a phase I study of BSO administered with the anticancer drug melphalan to determine the combination's safety/tolerability and to determine clinically whether BSO produced the desired ..
  24. ncbi Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial
    A M Eggermont
    Department of Surgical Oncology, University Hospital Rotterdam Daniel den Hoed Cancer Center, The Netherlands
    J Clin Oncol 14:2653-65. 1996
    ..limb perfusion (ILP) with tumor necrosis factor-alpha (TNF) in combination with interferon-gamma (IFN) and melphalan as induction therapy to render tumors resectable and avoid amputation in patients with nonresectable extremity ..
  25. ncbi Efficacy and complications of super-selective intra-ophthalmic artery melphalan for the treatment of refractory retinoblastoma
    Wisam J Muen
    Retinoblastoma Unit, Barts and The London NHS Trust, Royal London Hospital, United Kingdom
    Ophthalmology 119:611-6. 2012
    To report the efficacy of super-selective intra-ophthalmic artery melphalan (IAM) for the treatment of refractory retinoblastoma and any associated complications of this treatment.
  26. ncbi Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials
    Peter M Fayers
    Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, United Kingdom
    Blood 118:1239-47. 2011
    ..Six randomized controlled trials, launched in or after 2000, compared melphalan and prednisone alone (MP) and with thalidomide (MPT). The effect on overall survival (OS) varied across trials...
  27. ncbi Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma
    A Palumbo
    Divisione di Ematologia dell Universita di Torino, AOU S Giovanni Battista, Turin, Italy
    Leukemia 24:1037-42. 2010
    ..non-comparative phase II trial evaluated the safety and efficacy of salvage therapy with lenalidomide, melphalan, prednisone and thalidomide (RMPT) in patients with relapsed/refractory multiple myeloma (MM)...
  28. ncbi High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study
    Martha Skinner
    Boston University School of Medicine, Boston, Massachusetts 02118, USA
    Ann Intern Med 140:85-93. 2004
    ..AL amyloidosis is a fatal disease resulting from tissue deposition of amyloid fibrils derived from monoclonal immunoglobulin light chains. Treatment with oral chemotherapy is minimally effective...
  29. ncbi Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial
    Cyrille Hulin
    Service d Hematologie, rue du Morvan, Centre Hospitalier Universitaire de Nancy Brabois, 54511 Vandoeuvre, France
    J Clin Oncol 27:3664-70. 2009
    Until recently, melphalan and prednisone were the standards of care in elderly patients with multiple myeloma. The addition of thalidomide to this combination demonstrated a survival benefit for patients age 65 to 75 years...
  30. ncbi Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma
    Heinz Ludwig
    Department of Medicine I, Wilhelminenspital Vienna, Vienna, Austria
    Blood 113:3435-42. 2009
    We compared thalidomide-dexamethasone (TD) with melphalan-prednisolone (MP) in 289 elderly patients with multiple myeloma (MM)...
  31. ncbi The Prospective Oral Mucositis Audit: relationship of severe oral mucositis with clinical and medical resource use outcomes in patients receiving high-dose melphalan or BEAM-conditioning chemotherapy and autologous SCT
    S McCann
    Department of Haematology, St James s Hospital, Dublin, Ireland
    Bone Marrow Transplant 43:141-7. 2009
    ..in 197 patients with multiple myeloma (MM) or non-Hodgkin's lymphoma (NHL) undergoing, respectively, high-dose melphalan or BEAM chemotherapy and autologous SCT at 25 European centres...
  32. ncbi The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis
    E Terpos
    Department of Hematology and Medical Research, 251 General Air Force Hospital, Athens, Greece
    Leukemia 22:2247-56. 2008
    This phase 2 study aimed to determine the efficacy and safety of the combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide (VMDT) and its effect on bone remodeling and angiogenesis in relapsed/refractory ..
  33. ncbi Reduced intensity conditioning with thiotepa, fludarabine, and melphalan is effective in advanced multiple myeloma
    Ignazio Majolino
    Hematology and Bone Marrow Transplantation Unit, Azienda Ospedaliera S Camillo Forlanini, Rome, Italy
    Leuk Lymphoma 48:759-66. 2007
    ..siblings using a reduced-intensity conditioning consisting of thioteopa 5 mg/kg, fludarabine 90 mg/m(2), and melphalan 80 mg/m(2). Their median age was 52 years (range 38 - 68) and the interval from diagnosis 12 months...
  34. ncbi Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial
    Antonio Palumbo
    Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliera S Giovanni Battista, Torino, Italy
    Blood 112:3107-14. 2008
    The initial analysis of the oral combination melphalan, prednisone, and thalidomide (MPT) in newly diagnosed patients with myeloma showed significantly higher response rate and longer progression-free survival (PFS) than did the standard ..
  35. ncbi Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation
    A Spencer
    Clinical Haematology and BMT, The Alfred Hospital, Melbourne, Australia
    Bone Marrow Transplant 35:971-7. 2005
    ..transplantation (ASCT) were randomised to receive (n=43) or not receive (n=47) amifostine 910 mg/m(2) prior to melphalan 200 mg/m(2)...
  36. pmc Phase I study of hepatic arterial melphalan infusion and hepatic venous hemofiltration using percutaneously placed catheters in patients with unresectable hepatic malignancies
    James F Pingpank
    Surgical Metabolism Section, Surgery Branch, National Cancer Institute National Institutes of Health, Bethesda, MD 20892 1502, USA
    J Clin Oncol 23:3465-74. 2005
    We conducted a phase I study of a 30-minute hepatic artery infusion of melphalan via a percutaneously placed catheter and hepatic venous hemofiltration using a double balloon catheter positioned in the retrohepatic inferior vena cava to ..
  37. ncbi Targeted delivery of tumor necrosis factor-alpha to tumor vessels induces a therapeutic T cell-mediated immune response that protects the host against syngeneic tumors of different histologic origin
    Enrica Balza
    Department of Translational Oncology, Istituto Nazionale per la Ricerca sul Cancro, Unit of Innovative Therapies, Istituto Giannina Gaslini, Centro Biotecnologie Avanzate, Genoa, Italy
    Clin Cancer Res 12:2575-82. 2006
    ..for the oncofetal ED-B domain of fibronectin and tumor necrosis factor alpha, TNFalpha) in combination with melphalan induced complete and long-lasting tumor eradication in tumor-bearing mice and triggered the generation of a ..
  38. ncbi Pegfilgrastim compared with filgrastim after high-dose melphalan and autologous hematopoietic peripheral blood stem cell transplantation in multiple myeloma patients
    Massimo Martino
    Bone Marrow Transplant Unit, Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italy
    Eur J Haematol 77:410-5. 2006
    We undertook a comparative study of Pegfilgrastim vs. Filgrastim after high-dose melphalan and autologous peripheral blood stem cell transplantation (APBSCT) in multiple myeloma (MM) patients...
  39. ncbi Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors
    Naoto T Ueno
    Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 448, Houston, TX 77030, USA
    Blood 102:3829-36. 2003
    We evaluated the feasibility and efficacy of a reduced-intensity conditioning (RIC) regimen of fludarabine and melphalan to achieve rapid complete donor chimerism after allogeneic stem cell transplantation (SCT) in patients with ..
  40. ncbi Apoptosis of human carcinoma cells in the presence of potential anti-cancer drugs: III. Treatment of Colo-205 and SKBR3 cells with: cis -platin, Tamoxifen, Melphalan, Betulinic acid, L-PDMP, L-PPMP, and GD3 ganglioside
    Subhash Basu
    Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN 46556, USA
    Glycoconj J 20:563-77. 2004
    ..Cancer cells are non-apoptotic. Seven anti-cancer agents (cis -platin, Tamoxifen, Melphalan, Betulinic acid, D-PDMP, L-PPMP, and GD3) have been tested with human breast (SKBR3) and colon (Colo-205) ..
  41. ncbi Pentoxifyllin attenuates the systemic inflammatory response induced during isolated limb perfusion with recombinant human tumor necrosis factor-alpha and melphalan
    Peter Hohenberger
    Division of Surgery and Surgical Oncology, Robert Rössle Hospital and Tumor Institute, Max Delbruck Center for Molecular Medicine, Berlin, Germany
    Ann Surg Oncol 10:562-8. 2003
    Isolated limb perfusion (ILP) with recombinant human tumor necrosis factor-alpha (rhTNF-alpha) and melphalan harbors the risk of septic shock-like syndrome...
  42. ncbi Isolated hepatic perfusion for the treatment of patients with colorectal cancer liver metastases after irinotecan-based therapy
    H Richard Alexander
    Surgical Metabolism Section, Surgery Branch, Center for Cancer Research, National Cancer Institute, 10 Center Drive, Bethesda, Maryland 20892 1502, USA
    Ann Surg Oncol 12:138-44. 2005
    ..However, the response duration is <1 year, and second-line systemic chemotherapy has limited efficacy. We analyzed the efficacy of isolated hepatic perfusion (IHP) for patients with progressive CRC liver metastases after irinotecan...
  43. ncbi Therapy-induced antitumor vaccination by targeting tumor necrosis factor alpha to tumor vessels in combination with melphalan
    Lorenzo Mortara
    Department of Clinical and Biological Sciences, School of Medicine, University of Insubria, Varese, Italy
    Eur J Immunol 37:3381-92. 2007
    ..targeted to tumor vasculature by the anti-ED-B fibronectin domain antibody L19(scFv) and combined with melphalan, induces a therapeutic immune response...
  44. ncbi Effectiveness of regional chemotherapy with TNF-alpha/melphalan in advanced soft tissue sarcoma of the extremities
    G Taeger
    West German Cancer Centre, University Hospital of Essen, Marburg, Germany
    Int J Hyperthermia 24:193-203. 2008
    Hyperthermic isolated limb perfusion with tumour necrosis factor alpha (TNF-alpha) and melphalan was repeatedly reported to achieve extraordinarily high clinical remission rates in advanced and non-resectable soft tissue sarcoma of the ..
  45. ncbi A phase I/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results
    David H Abramson
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Ophthalmology 115:1398-404, 1404.e1. 2008
    ..to cannulate repeatedly the ophthalmic artery of young children with advanced retinoblastoma, to find a dose of melphalan that would be tolerable and tumoricidal for retinoblastoma when given intraarterially, and to study the local ..
  46. ncbi Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure
    Andrew Spencer
    Malignant Haematology and Stem Cell Transplantation Service, Alfred Hospital, Melbourne, Victoria, Australia
    J Clin Oncol 27:1788-93. 2009
    ..This study assessed whether the addition of thalidomide consolidation following ASCT would improve the durability of responses achieved and overall survival...
  47. ncbi Isolated hepatic perfusion with high-dose melphalan results in immediate alterations in tumor gene expression in patients with metastatic ocular melanoma
    Sheelu Varghese
    Department of Surgery, University of Maryland School of Medicine, Baltimore, MD, USA
    Ann Surg Oncol 17:1870-7. 2010
    ..In this study, we characterized the early molecular changes that occur in tumors immediately after vascular isolation perfusion with melphalan with hyperthermia in patients with hepatic metastases from ocular melanoma.
  48. ncbi Pegfilgrastim reduces the length of hospitalization and the time to engraftment in multiple myeloma patients treated with melphalan 200 and auto-SCT compared with filgrastim
    Panagiotis Samaras
    Department of Oncology, University Hospital Zurich, Ramistrasse 100, 8091, Zurich, Switzerland
    Ann Hematol 90:89-94. 2011
    ..engraftment, hospital stay, and supportive measures in patients with multiple myeloma after conditioning with Melphalan 200 (Mel200) followed by APBSCT...
  49. ncbi Tumor vascularization and histopathologic regression of soft tissue sarcomas treated with isolated limb perfusion with TNF-α and melphalan
    Florian Grabellus
    Institute of Pathology and Neuropathology, Sarcoma Center, West German Cancer Center, University Hospital of Essen, University of Duisburg Essen, Essen, Germany
    J Surg Oncol 103:371-9. 2011
    ..Some tumors show an insufficient association between radiological and pathological response. We investigated STS after TM-ILP with a primary emphasis on histologic regression patterns...
  50. ncbi Isolated limb perfusion with TNF-alpha and melphalan for distal parts of the limb in soft tissue sarcoma patients
    Jan P Deroose
    Division of Surgical Oncology, Daniel den Hoed Erasmus MC, Rotterdam, The Netherlands
    J Surg Oncol 105:563-9. 2012
    ..Tumor necrosis factor-alpha (TNF) and melphalan-based isolated limb perfusion (TM-ILP) is effective in locally advanced STS of the extremities...
  51. pmc Generation of a predictive melphalan resistance index by drug screen of B-cell cancer cell lines
    Martin Boegsted
    Department of Haematology, Aalborg Hospital Science and Innovation Center, Aarhus University Hospital, Aalborg, Denmark
    PLoS ONE 6:e19322. 2011
    ..MM) a range of new drugs have been introduced and now challenge conventional therapy including high dose melphalan. Consequently, the generation of predictive signatures for response to melphalan may have a clinical impact...
  52. ncbi Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial
    Maria Victoria Mateos
    Hospital Universitario de Salamanca, Paseo San Vicente 58 182, 37007 Salamanca, Spain
    J Clin Oncol 28:2259-66. 2010
    The purpose of this study was to confirm overall survival (OS) and other clinical benefits with bortezomib, melphalan, and prednisone (VMP) versus melphalan and prednisone (MP) in the phase III VISTA (Velcade as Initial Standard Therapy ..
  53. ncbi Association between transcriptional activity, local chromatin structure, and the efficiencies of both subpathways of nucleotide excision repair of melphalan adducts
    Hara Episkopou
    Institute of Biological Research and Biotechnology, National Hellenic Research Foundation, Athens, Greece
    Cancer Res 69:4424-33. 2009
    The repair of melphalan-induced N-alkylpurine monoadducts and interstrand cross-links was examined in different repair backgrounds, focusing on four genes (beta-actin, p53, N-ras, and delta-globin) with dissimilar transcription ..
  54. ncbi Resveratrol chemosensitizes breast cancer cells to melphalan by cell cycle arrest
    Fabiana Casanova
    Universidade Federal do Rio de Janeiro, Instituto de Bioquimica Medica, Rio de Janeiro, RJ 21941 590, Brazil
    J Cell Biochem 113:2586-96. 2012
    b>Melphalan (MEL) is a chemotherapeutic agent used in breast cancer therapy; however, MEL's side effects limit its clinical applications...
  55. pmc Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study
    Martin Hjorth
    Department of Medicine, Lidköping Hospital, Lidköping, Sweden
    Eur J Haematol 88:485-96. 2012
    ..have been frequently used for second-line therapy in patients with myeloma relapsing after or refractory to initial melphalan-based treatment, but no randomized trials have been published comparing these two treatment alternatives.
  56. ncbi Technique and results of hyperthermic isolated hepatic perfusion with tumor necrosis factor and melphalan for the treatment of unresectable hepatic malignancies
    S K Libutti
    Surgical Metabolism Section, Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1502, USA
    J Am Coll Surg 191:519-30. 2000
    ..This article describes the technique of isolated hepatic perfusion using tumor necrosis factor and melphalan under conditions of moderate hyperthermia for the treatment of unresectable liver tumors...
  57. ncbi Intermediate doses of melphalan and dexamethasone are better than vincristine, adriamycin, and dexamethasone (VAD) and polychemotherapy for the treatment of primary plasma cell leukemia
    J Vela-Ojeda
    Department of Hematology, Hospital de Especialidades Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social, Apartado postal 14 878, Código postal 07001, Mexico D F, Mexico
    Ann Hematol 81:362-7. 2002
    ..Four patients were treated with vincristine, melphalan, cyclophosphamide, prednisone, and adriamycin (VMCPA), 12 with vincristine, adriamycin, and dexamethasone (VAD), ..
  58. ncbi Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial
    Antonio Palumbo
    Divisione di Ematologia dell Universita di Torino, Ospedale Molinette, Via Genova 3, 10126 Torino, Italy
    Blood 104:3052-7. 2004
    ..study, 194 patients were randomized to receive at diagnosis either conventional chemotherapy (6 courses of oral melphalan and prednisone [MP]) or intermediate-dose therapy (2 courses of melphalan at 100 mg/m(2) [MEL100]) with stem ..
  59. pmc High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement
    Sumit Madan
    Division of Hematology, Department of Medicine, Mayo Clinic, 200 First Street, Rochester, MN 55905, USA
    Blood 119:1117-22. 2012
    High-dose melphalan (HDM) plus stem cell transplantation is an effective treatment for light-chain amyloidosis (AL), but is associated with high treatment-related mortality in patients with cardiac involvement...
  60. ncbi Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC)
    Stephane Vigouroux
    Service d Hematologie Clinique, Centre Hospitalier Universitaire CHU Pontchaillou, Rennes, France
    Haematologica 92:627-34. 2007
    ..The aim of this study was to determine the outcome of patients with LGL treated with RIC allogeneic SCT...
  61. ncbi Long-term results of melphalan-based isolated limb perfusion with or without low-dose TNF for in-transit melanoma metastases
    Carlo Riccardo Rossi
    Department of Oncological and Surgical Sciences, University of Padova, Padova, Italy
    Ann Surg Oncol 17:3000-7. 2010
    ..of the perfused patients; (2) to compare toxicity, response, and survival among patients who underwent melphalan-based perfusion with or without low-dose tumor necrosis factor (TNF); and (3) to identify factors that predict a ..
  62. ncbi BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients
    Giuseppe Visani
    Hematology and Stem Cell Transplant Center, Marche Nord Hospital, Pesaro, Italy
    Blood 118:3419-25. 2011
    ..180 mg/m², and 200 mg/m² given on days -7 and -6) coupled with fixed doses of etoposide, cytarabine, and melphalan (BeEAM regimen) as the conditioning regimen to autologous stem cell transplantation for resistant/relapsed ..
  63. ncbi Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma
    Victoria J Spanswick
    Cancer Research UK Drug DNA Interactions Research Group, Department of Oncology, Royal Free and University College Medical School, London, United Kingdom
    Blood 100:224-9. 2002
    b>Melphalan is widely used as a preparative agent in patients with multiple myeloma (MM) undergoing autologous stem cell transplantation (SCT)...
  64. ncbi Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone
    D Lebovic
    Department of Medicine, Weill Cornell School of Medicine, New York Hospital, NY, USA
    Br J Haematol 143:369-73. 2008
    ..AL cardiac patients who were not candidates for stem cell transplant and therefore received monthly oral melphalan and dexamethasone. Median survival was 10...
  65. ncbi Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group
    Meral Beksac
    Department of Hematology, Faculty of Medicine, Ankara University, Ankara, Turkey
    Eur J Haematol 86:16-22. 2011
    The combination of melphalan-prednisone-thalidomide (MPT) has been investigated in several clinical studies that differed significantly with regard to patient characteristics and treatment schedules...
  66. ncbi Hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan in patients with locally advanced soft tissue sarcomas: treatment response and clinical outcome related to changes in proliferation and apoptosis
    B E Plaat
    Department of Pathology, University Hospital Groningen, The Netherlands
    Clin Cancer Res 5:1650-7. 1999
    Hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan (HILP-TM) with or without IFN-gamma is a promising local treatment in patients with locally advanced extremity soft tissue sarcomas (STSs), with response ..
  67. ncbi Selective ophthalmic arterial injection therapy for intraocular retinoblastoma: the long-term prognosis
    Shigenobu Suzuki
    Division of Ophthalmic Oncology, National Cancer Center Hospital, Tokyo, Japan
    Ophthalmology 118:2081-7. 2011
    ..To report the success rate, adverse events, and long-term prognosis of selective ophthalmic arterial injection (SOAI) therapy for intraocular retinoblastoma...
  68. ncbi Hyperthermia modifies pharmacokinetics and tissue distribution of intraperitoneal melphalan in a rat model
    O Glehen
    Surgical Department, Centre Hospitalo Universitaire Lyon Sud, 69495 Pierre Benite, France
    Cancer Chemother Pharmacol 54:79-84. 2004
    ..b>Melphalan is a chemotherapeutic agent that shows increased pharmacological activity with heat...
  69. ncbi Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis
    Nelson Leung
    Division of Nephrology, Mayo Clinic, Rochester, MN 55905, USA
    Am J Kidney Dis 46:270-7. 2005
    ..High-dose melphalan followed by autologous stem cell transplantation currently has become the treatment of choice...
  70. pmc Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats
    J H de Wilt
    Department of Surgical Oncology, University Hospital Rotterdam Dijkzigt Daniel den Hoed Cancer Centre, Rotterdam, The Netherlands
    Br J Cancer 80:161-6. 1999
    ..Combination of 50 microg TNF and 40 microg melphalan demonstrated synergistic activity leading to a partial and complete response rate of 71%...
  71. pmc Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3,000 patients treated since 1989
    Bart Barlogie
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 W Markham, Little Rock, AR 72205, USA
    Blood 111:94-100. 2008
    ..While the risk of MDS-CAs was low and clinical MDS occurred infrequently, monitoring after post-HDT consolidation chemotherapy appears warranted...
  72. ncbi Melphalan as a treatment for BRCA-related ovarian carcinoma: can you teach an old drug new tricks?
    Deidra J Osher
    Department of Medical Genetics, McGill University Health Centre, Montreal, Quebec, Canada
    J Clin Pathol 64:924-6. 2011
    ..The patient was subsequently treated with oral melphalan therapy and has not recurred in over 25 years...
  73. ncbi Expression of multidrug resistance genes MVP, MDR1, and MRP1 determined sequentially before, during, and after hyperthermic isolated limb perfusion of soft tissue sarcoma and melanoma patients
    Ulrike Stein
    Division of Surgery and Surgical Oncology, Charite, Humboldt University, Campus Berlin Buch, Robert Rössle Hospital and Tumor Institute, Robert Rossle Strasse 10, 13092 Berlin, Germany
    J Clin Oncol 20:3282-92. 2002
    Isolated, hyperthermic limb perfusion (ILP) with recombinant human tumor necrosis factor alpha and melphalan is a highly effective treatment for advanced soft tissue sarcoma (STS) and locoregional metastatic malignant melanoma...
  74. ncbi Lenalidomide plus dexamethasone vs. lenalidomide plus melphalan and prednisone: a retrospective study in newly diagnosed elderly myeloma
    Francesca Gay
    Department of Internal Medicine, Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN, USA
    Eur J Haematol 85:200-8. 2010
    The goal of this retrospective study was to compare the efficacy and toxicity of lenalidomide-dexamethasone (len/dex) vs. melphalan-prednisone-lenalidomide (MPR) as upfront therapy for newly diagnosed elderly patients with myeloma.
  75. ncbi Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation
    Giovanni Palladini
    Amyloid Center Biotechnology Research Laboratories, Department of Biochemistry, University Hospital, Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy
    Blood 103:2936-8. 2004
    ..Patients ineligible for ASCT are usually treated with standard oral melphalan and prednisone, but the response rate to this regimen is unsatisfactory, and time to response is long...
  76. pmc Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience
    Paolo Anderlini
    The U T M D Anderson Cancer Center, Department of Stem Cell Transplantation and Cellular Therapy 1515 Holcombe Boulevard, Unit 423, Houston, TX 77030 USA
    Haematologica 93:257-64. 2008
    ..We here present an update of our single-center experience with fludarabine-melphalan as a preparative regimen.
  77. ncbi Changes in quality-of-life and psychosocial adjustment among multiple myeloma patients treated with high-dose melphalan and autologous stem cell transplantation
    Allen C Sherman
    Behavioral Medicine, Winthrop P Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Biol Blood Marrow Transplant 15:12-20. 2009
    High-dose melphalan and autologous hematopoietic stem cell transplantation (HSCT) is a standard treatment for myeloma, but very little is known about the psychosocial or quality-of-life difficulties that these patients encounter during ..
  78. ncbi High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis
    Arnaud Jaccard
    Department of Hematology, Centre Hospitalier Universitaire, Université et Centre National de la Recherche Scientifique, UMR 6101, Limoges, France
    N Engl J Med 357:1083-93. 2007
    ....
  79. pmc Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation
    Vaishali Sanchorawala
    Stem Cell Transplantation Program of the Section of Hematology Oncology, Boston University School of Medicine, Boston, MA 02118, USA
    Blood 110:3561-3. 2007
    ..outcome were determined for 80 patients with immunoglobulin light chain (AL) amyloidosis treated with high-dose melphalan and stem cell transplantation (HDM/SCT) more than 10 years ago...
  80. ncbi Substitution of cyclophosphamide and busulfan by fludarabine, treosulfan and melphalan in a preparative regimen for children and adolescents with Shwachman-Diamond syndrome
    M Sauer
    Department of Pediatric Hematology Oncology, Hannover Medical University, Hannover, Germany
    Bone Marrow Transplant 39:143-7. 2007
    ..In an attempt to minimize regimen-related toxicity (RRT), we have initiated a fludarabine/treosulfan/melphalan-based pilot protocol avoiding the combination of busulfan and cyclophosphamide...
  81. ncbi Isolated limb perfusion with tumor necrosis factor and melphalan for non-resectable soft tissue sarcomas: long-term results on efficacy and limb salvage in a selected group of patients
    Stephane Cherix
    Department of Orthopaedic Surgery, University Hospital, Lausanne, Switzerland
    J Surg Oncol 98:148-55. 2008
    Isolated limb perfusion with TNF-alpha and melphalan (TM-ILP) is a limb salvage therapy for non-resectable soft tissue sarcomas (STS) of the extremities...
  82. ncbi Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma
    Danielle N Yarde
    Cancer Biology Ph D Program, University of South Florida, Tampa, Florida 33612, USA
    Cancer Res 69:9367-75. 2009
    ..We recently reported that FA/BRCA genes are overexpressed and causative for drug resistance in human melphalan-resistant multiple myeloma cell lines...
  83. ncbi Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma
    Anders Waage
    Department of Hematology, St Olavs Hospital, Norwegian University of Science and Technology, Trondheim, Norway
    Blood 116:1405-12. 2010
    ..placebo-controlled study, 363 patients with untreated multiple myeloma were randomized to receive either melphalan-prednisone and thalidomide (MPT) or melphalan-prednisone and placebo (MP). The dose of melphalan was 0...
  84. ncbi High-dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewing's sarcoma does not improve prognosis
    P A Meyers
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 19:2812-20. 2001
    To determine whether consolidation therapy with high-dose melphalan, etoposide, and total-body irradiation (TBI) with autologous stem-cell support would improve the prognosis for patients with newly diagnosed metastatic Ewing's sarcoma (..
  85. ncbi High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma
    J Anthony Child
    Academic Unit of Haematology and Oncology, Cancer Research United Kingdom Clinical Centre, University of Leeds, Leeds, United Kingdom
    N Engl J Med 348:1875-83. 2003
    ..In multiple myeloma, first-line regimens incorporating high-dose therapy yield higher remission rates than do conventional-dose treatments, but evidence that this translates into improved survival is limited...
  86. ncbi Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: long-term follow-up of the Dutch Cooperative Group HOVON 24 trial
    Pieter Sonneveld
    Erasmus Medical Center Rotterdam, The Netherlands
    Haematologica 92:928-35. 2007
    ..The Dutch-Belgian HOVON group performed a randomized phase 3 trial to compare single non-myeloablative intensive treatment with double, intensive treatment in previously untreated patients with multiple myeloma (MM)...
  87. ncbi Thalidomide versus bortezomib based regimens as first-line therapy for patients with multiple myeloma: a systematic review
    Ambuj Kumar
    Center for Evidence based Medicine and Health Outcome Research, University of South Florida
    Am J Hematol 86:18-24. 2011
    Thalidomide (T) or bortezomib (B) in combination with melphalan plus prednisone (MP) is superior to MP as first line therapy for previously untreated myeloma...
  88. ncbi Thalidomide and hematopoietic-cell transplantation for multiple myeloma
    Bart Barlogie
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    N Engl J Med 354:1021-30. 2006
    High-dose therapy with melphalan can prolong survival among patients with multiple myeloma. We assessed whether the addition of thalidomide, which has activity against advanced and refractory myeloma, would further improve survival.
  89. ncbi Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma
    Michel Delforge
    Myeloma Study Group, Belgian Hematological Society, Belgium
    Eur J Haematol 86:372-84. 2011
    ..This post hoc analysis of the phase III VISTA trial of bortezomib plus melphalan-prednisone (VMP) vs...
  90. ncbi Evaluation of 47 soft tissue sarcoma resection specimens after isolated limb perfusion with TNF-alpha and melphalan: histologically characterized improved margins correlate with absence of recurrences
    Florian Grabellus
    Institute of Pathology and Neuropathology, University Hospital Essen and Sarcoma Center at the West German Cancer Center, University of Duisburg Essen, 45122 Essen, Germany
    Ann Surg Oncol 16:676-86. 2009
    ..Isolated limb perfusion (TM-ILP) is an effective limb-sparing treatment for primarily nonresectable soft tissue sarcomas (STS). Surgical margins of STS after ILP were yet not systematically studied...
  91. ncbi Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study
    Maria Victoria Mateos
    Hematology Division, Grupo Español de MM, Spain Paseo San Vicente 58 182 37007 Salamanca, Spain
    Blood 108:2165-72. 2006
    ..first-line treatment for elderly multiple myeloma (MM) patients ineligible for stem cell transplantation is melphalan plus prednisone (MP). However, complete responses (CRs) are rare...
  92. pmc Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion
    J H de Wilt
    Department of Surgical Oncology, University Hospital Rotterdam Dijkzigt Daniel den Hoed Cancer Centre, The Netherlands
    Br J Cancer 82:1000-3. 2000
    ..possible mechanisms for the synergistic anti-tumour effects between tumour necrosis factor alpha (TNF-alpha) and melphalan after isolated limb perfusion (ILP) have been presented...
  93. ncbi Synergistic cytotoxicity of buthionine sulfoximine (BSO) and intensive melphalan (L-PAM) for neuroblastoma cell lines established at relapse after myeloablative therapy
    C P Anderson
    Division of Hematology Oncology, Childrens Hospital Los Angeles, CA 90027, USA
    Bone Marrow Transplant 30:135-40. 2002
    ..We examined the ability of buthionine sulfoximine (BSO)-mediated glutathione (GSH) depletion to modulate melphalan (L-PAM) resistance in five NB cell lines established after progressive disease following myeloablative therapy (..
  94. ncbi Aneugenic potential of the nitrogen mustard analogues melphalan, chlorambucil and p-N,N-bis(2-chloroethyl)aminophenylacetic acid in cell cultures in vitro
    M Efthimiou
    Division of Genetics, Cell and Developmental Biology, Department of Biology, University of Patras, Patras 265 00, Greece
    Mutat Res 617:125-37. 2007
    b>Melphalan (MEL), chlorambucil (CAB) and p-N,N-bis(2-chloroethyl)aminophenylacetic acid (PHE) are nitrogen mustard analogues, which are clinically used as chemotherapeutic agents. They also exert carcinogenic activity...
  95. ncbi A phase 1 study of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with locally advanced in-transit malignant melanoma
    Georgia M Beasley
    Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Cancer 115:4766-74. 2009
    Isolated limb infusion with melphalan is a well-tolerated treatment for patients with in-transit extremity melanoma with an approximately 30% complete response (CR) rate...
  96. ncbi p53 status correlates with histopathological response in patients with soft tissue sarcomas treated using isolated limb perfusion with TNF-alpha and melphalan
    J Muret
    Department of AnesthesiaInstitut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
    Ann Oncol 19:793-800. 2008
    Recombinant tumor necrosis factor-alpha (TNF-alpha) combined to melphalan is clinically administered through isolated limb perfusion (ILP) for regionally advanced soft tissue sarcomas of the limbs...
  97. ncbi Adenine-containing DNA-DNA cross-links of antitumor nitrogen mustards
    Shawn Balcome
    Department of Medicinal Chemistry, University of Minnesota Cancer Center, Room 760E, Box 806 Mayo, 420 Delaware Street Southeast, Minneapolis, Minnesota 55455, USA
    Chem Res Toxicol 17:950-62. 2004
    ..The presence of cross-linked adenine-adenine lesions may explain the enhanced cytotoxicity and mutagenicity of NMs in cells deficient in N3-alkyladenine glycosylase...
  98. ncbi Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020
    Wendy R Cornett
    The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 24:4196-201. 2006
    ..prospective multi-institutional trial whether the addition of tumor necrosis factor alpha (TNF-alpha) to a melphalan-based hyperthermic isolated limb perfusion (HILP) treatment would improve the complete response rate for locally ..
  99. ncbi Novel amidine analogue of melphalan as a specific multifunctional inhibitor of growth and metabolism of human breast cancer cells
    Krzysztof Bielawski
    Department of Medicinal Chemistry and Drug Technology, Medical University of Białystok, Kilinskiego 1, 15 089 Białystok, Poland
    Biochem Pharmacol 72:320-31. 2006
    A novel amidine analogue of melphalan (AB4) was compared to its parent drug, melphalan in respect to cytotoxicity, DNA and collagen biosynthesis in MDA-MB-231 and MCF-7 human breast cancer cells...
  100. ncbi Acute left ventricular failure following melphalan and fludarabine conditioning
    D S Ritchie
    Bone Marrow Transplant Service, Department of Clinical Haematology and Medical Oncology, Royal Melbourne Hospital, Melbourne, Australia
    Bone Marrow Transplant 28:101-3. 2001
    Cardiotoxicity has rarely been reported as a complication of melphalan or fludarabine administration as single agents...
  101. ncbi CD34+ cell dose and establishment of full donor chimerism at day +100 are important factors for survival with reduced-intensity conditioning with fludarabine and melphalan before allogeneic hematopoietic SCT for hematologic malignancies
    S G Holtan
    Division of Hematology, Department of Medicine, Mayo Clinic Graduate School of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Bone Marrow Transplant 45:1699-703. 2010
    The combination of fludarabine and melphalan as a reduced-intensity conditioning (RIC) regimen extends allogeneic hematopoietic SCT (HSCT) as a therapeutic option for elderly or frail patients with relapsed, refractory or other high-risk ..

Research Grants62

  1. Nebraska/Kansas Blood and Marrow Transplant Research Network
    JULIE MARIE VOSE; Fiscal Year: 2013
    ..for patients with relapsed diffuse large B-cell lymphoma using Rituximab/Carmustine, Etoposide, Cytarabine, and Melphalan (R-BEAM) or Bexxar/BEAM + autologous HSCT as the control and R-BEAM or Bexxar/BEAM + autologous HSCT + ..
  2. Detoxification of Electrophilic Chemical Threat Agents by Nucleophilic Scavengers
    Michael C MacLeod; Fiscal Year: 2010
    ..Both of these have been shown to completely detoxify the carcinogen BPDE. DTP has also been shown to detoxify melphalan, a nitrogen mustard, and in preliminary studies we have demonstrated facile reaction of DTP with a sulfur ..
  3. Systemic Chemotherapy of Melanoma: NMR Studies of Lonidamine &N-Mustard Activity
    Jerry D Glickson; Fiscal Year: 2013
    ..b>Melphalan (LPAM 7.5 mg/kg i.v.)+ LND exhibited a growth delay of 10.5[unreadable]0.5 d vs. LND alone, 0.6[unreadable]0.7 d...
  4. Microenvironment Function Following Chemotherapy
    Laura F Gibson; Fiscal Year: 2013
    ..Pilot data relevant to the current application indicate that primary human osteoblasts exposed to melphalan or VP-16 have diminished CXCL12 expression and chemotactic support and altered support of CD34+ bone marrow cell ..
  5. Mechanism of Activity of Lonidamine
    Jerry D Glickson; Fiscal Year: 2013
    ..We have recently shown that administration of lonidamine (LND, 100 mg/kg) substantially enhances the activity of melphalan and have now extended this finding to doxorubicin treatment...
  6. Predicting Chemotherapy-Induced Mucositis with Genetic and Clinical Factors
    ELIZABETH ANN contact COLEMAN; Fiscal Year: 2010
    ..Severe mucositis is a dose limiting toxicity of high dose melphalan (MEL) with autologous stem cell transplant (ASCT), the cornerstone of treatment of myeloma and other cancers ..
  7. Improving current therapies for myeloma
    DAN TOBY VOGL; Fiscal Year: 2013
    ..3) To determine, in a prospective cohort study, whether administration of high-dose melphalan induces autophagy in malignant plasma cells purified from patient bone marrow samples...
  8. Core Clinical Consortium for Blood and Marrow Transplant Clinical Trials Network
    John R Wingard; Fiscal Year: 2013
    ..the optimal conditioning regimen for the first HSCT of myeloma patients testing the combination of high-dose melphalan plus bortezomib versus melphalan alone as conditioning prior to autologous hematopoietic stem cell ..
  9. Inhibition of glutathione reductase and ovarian cancer drug resistance reversal
    Xiangming Guan; Fiscal Year: 2006
    ..first and rate-determining step in GSH biosynthesis significantly increased the sensitivity of the cell line to melphalan, a chemotherapeutic agent...
  10. DETECTION & REVERSAL OF OVARIAN CANCER DRUG RESISTANCE
    Robert Ozols; Fiscal Year: 1992
    ..pharmacologic depletion of GSH levels with buthionine sulfoximine (BSO) leads to potentiation of cytotoxicity of melphalan and carboplatin, (2) inhibition of GST with ethacrynic acid potentiates the cytotoxicity in vitro and in vivo of ..
  11. HYPOTHALAMIC HORMONES IN PANCREATIC CANCER
    Andrew Schally; Fiscal Year: 1991
    ..5) Synthesis of somatostatin analogs containing cytostatic radicals such as Melphalan, Aziridine, Mitomycin C and their evaluation in models of pancreatic cancer as targeted hormonal carriers for ..
  12. GLUTATHIONE AND RESISTANCE TO CANCER CHEMOTHERAPY
    Owen Griffith; Fiscal Year: 2000
    DESCRIPTION: (Applicant's Abstract) Bifunctional alkylating agents (e.g., melphalan, cyclophosphamide, chlorambucil) and platinum antitumor compounds (e.g. cisplatin, carboplatin) are used to treat a wide range of human malignancies...
  13. PEDIATRIC ONCOLOGY GROUP
    Stephen Lauer; Fiscal Year: 2002
    ..relapsed AML with idarubicin and chlordeoxyadenosine, treatment of relapsed solid tumors with high-dose busulfan/melphalan and ABMT, transplantation of haploidentical CD34+ cells for relapsed ALL or AML, and vincristine plus dose-..
  14. Minor Histocompatilibity Vaccination After Allo-Transpl*
    Koen Van Besien; Fiscal Year: 2004
    ..The conditioning regimen will consist of fludarabine-melphalan-campath...
  15. Glutathione reductase and tumor sensitivity to radiation
    Xiangming Guan; Fiscal Year: 2003
    ..of GR did reduce intracellular GSH and the reduction of GSH led to an increase in the sensitivity of OVCAR-3 to melphalan, a chemotherapeutic agent...
  16. MicroRNAs Regulating The Fanconi Anemia-BRCA Pathway
    Toshiyasu Taniguchi; Fiscal Year: 2009
    ..by applicant): DNA-crosslinking agents such as cisplatin, carboplatin, cyclophosphamide, mitomycin C and melphalan are widely-used drugs for treatment of cancers including leukemia, lymphoma, and myeloma...
  17. DRUG SEQUENCING RESISTANCE IN MULTIPLE MYELOMA
    Daniel Sullivan; Fiscal Year: 1999
    ..1. To establish the toxicity and potential efficacy of a high-dose regimen sequenced as melphalan followed by topotecan followed by VP-16 phosphate (MTV) followed by peripheral blood stem cell rescue in the ..
  18. INTERACTION OF AMINOTHIOLS AND ALKYLATING AGENTS
    Frederick Valeriote; Fiscal Year: 1990
    ..We expect to determine from these studies whether this findings has potential clinical therapeutic application...
  19. GLUTATHIONE BIOSYSTHESIS AND DRUG RESISTANCE
    R Mulcahy; Fiscal Year: 1999
    ....
  20. LH-RH ANALOGS IN BREAST AND OVARIAN CANCER
    Andrew Schally; Fiscal Year: 1991
    ..chemotherapeutic agents; 5) continued synthesis of various LH-RH analogs containing cytostatic radicals such as Melphalan, Aziridine, Mitomycin C and their evaluation in models of breast and ovarian cancer as targeted hormonal ..
  21. PRIMARY BREAST CANCER THERAPY GROUP
    Henry Shibata; Fiscal Year: 1980
    ....
  22. Development of Anticancer 1,2-Bis(sulfonyl)hydrazines
    Alan Sartorelli; Fiscal Year: 2009
    ..brain barrier, is active both orally and parenterally, is not cross-resistant with cyclophosphamide, BCNU, or melphalan, and a by-product of its activation, methyl isocyanate, has synergistic cytotoxic activity with the generated ..
  23. MECHANISMS OF DRUG RESISTANCE IN MULTIPLE MYELOMA
    William Dalton; Fiscal Year: 1990
    ..Specifically, the mechanism of resistance to doxorubicin and its possible cross resistance with melphalan will be analyzed...
  24. USE OF LH-RH AGONISTS & ANTAGONISTS IN PROSTATE CANCER
    Andrew Schally; Fiscal Year: 1993
    ..2) continued synthesis of various agonists and antagonists of LH-RH containing cytotoxic radicals such as Melphalan, Aziridine and Mitomycin C, the evaluation of their binding to LH-RH receptors and testing of their effects in ..
  25. SYNERGY OF TUMOR CHEMOTHERAPY AND HOST IMMUMITY
    SHELDON DRAY; Fiscal Year: 1991
    A single injection of less than one-tenth of the maximal tolerable dose of cyclophosphamide or melphalan cures a BALB/c mouse bearing a large subcutaneous MOPC-315 plasmacytoma and extensive metastases at a late stage of tumor growth, ..
  26. Akylating agent Water-soluble Sulfonyl Hydrazine Prodrug
    Xu Lin; Fiscal Year: 2001
    ..Various alkylating agents are approved for the treatment of cancer including cyclophosphamide, busulfan, melphalan, nitrogen mustard, chlorambucil, and the nitrosoureas...
  27. PRIMARY BREAST CANCER THERAPY GROUP
    Roger Poisson; Fiscal Year: 1991
    ..An ancillary aim is to enhance the multidisciplinary capabilities of this institution in clinical trials...
  28. MELPHALAN PLUS AMIFOSTINE CYTOPROTECTION CANCER PATIENTS
    Gordon Phillips; Fiscal Year: 1999
    ..aim of this study is to evaluate the efficacy of amifostine in preventing excessive RRT of the chemotherapy drug melphalan used in "transplant doses" of 220mg/m2 and greater...
  29. ASSAY OF TUMOR INDUCTION BY X-RAY AND DRUG MODALITIES
    EDGAR RILEY; Fiscal Year: 1980
    ..We also monitor the weights of the rats after treatments and do periodic blood counts looking for hematopoietic changes. ..
  30. NEW ISOPHOSPHORAMIDE MUSTARD PRODRUGS
    David Farquhar; Fiscal Year: 2005
    ..activities against experimental tumors and human tumor xenografts in mice, (d) organ toxicities in the mouse, and (e) antitumor efficacy compared with IPM and melphalan when administered by limb perfusion in a rat sarcoma tumor model.
  31. PRIMARY BREAST CANCER THERAPY GROUP
    Roger Poisson; Fiscal Year: 1980
    ..This group has the same capability to accomplish any new breast cancer protocol as it has done for the protocols already mentioned...
  32. ROLE OF GRP78 IN ALKYLATING AGENT SENSITIVITY
    Satadal Chatterjee; Fiscal Year: 2005
    ..in V79 Chinese hamster cells is associated with potentiation of cytotoxicity inflicted by BCNU, cisplatin or melphalan as determined by clonogenic survival assays...
  33. A Novel Antibody Therapeutic for Multiple Myeloma
    Koteswara Chintalacharuvu; Fiscal Year: 2004
    ..Although conventional therapy of multiple myeloma with oral melphalan and prednisone can effect remissions in approximately 40% of patients, the disease remains incurable, with a ..
  34. INTERGROUP RHABDOMYOSARCOMA STUDY
    Gregory Reaman; Fiscal Year: 2002
    ..vs ifosfamide vs ifosfamide + VP-l6, and (2) rank ordering of induction drug doublets (vincristine/melphalan vs ifosfamide/etoposide vs ifosfamide doxorubicin) and their clinical cross-resistance to VAC therapy...
  35. NF-KB MEDIATED DRUG RESISTANCE IN OVARIAN CANCER
    David Spriggs; Fiscal Year: 2004
    ..The effect of NF-kappaB activation on resistance to the cytotoxicity of CDDP paclitaxel, melphalan, doxorubicin, topotecan and other agents will be examined...
  36. MECHANISM OF MELPHALAN-MEDIATED TUMOR ERADICATION
    MARGALIT MOKYR; Fiscal Year: 1990
    The main objective of this proposal is to understand the mechanism by which a widely used anticancer drug, melphalan (L- PAM) shifts the balance from immunosuppression to potent antitumor immunity when administered to mice at an advanced ..
  37. ALLO STEM CELL TRANSPLANT. FOR HIGH RISK HEMOTOLOGIC CA
    Gordon Phillips; Fiscal Year: 2000
    ..agents that are less likely to provoke these cytokines, namely busulfan (or, when busulfan can not be utilized, melphalan) and T10B9 (MEDI-500), a TCRalpha/beta monoclonal antibody in patients selected as requiring allo-SCT for ..
  38. MELPHALAN CYTOTOXICITY AND RESISTANCE IN MEDULLOBLASTOMA
    Henry Friedman; Fiscal Year: 1990
    ..specific mechanisms of drug sensitivity, delivery, and resistance in this tumor, and 2) L-phenylalanine mustard (melphalan) and other phenylalanine mustard isomers represent bifunctional alkylating agents highly cytoxic to human ..
  39. MECHANISM OF MELPHALAN-MEDIATED TUMOR ERADICATION
    MARGALIT MOKYR; Fiscal Year: 1992
    The main objective of this proposal is to understand the mechanism by which a widely used anticancer drug, melphalan (L- PAM); shifts the balance from immunosuppression to potent antitumor immunity when administered to mice at an ..
  40. MECHANISMS OF ENHANCEMENT OF MELPHALAN CYTOTOXICITY
    Thomas Guenthner; Fiscal Year: 1993
    ..proposed studies is to examine the biochemical mechanisms whereby the cytotoxicity of the DNAalkylating agent melphalan (L-phenylalanine mustard, LPAM) to human melanoma cells is enhanced by the coadministration of two agents, ..
  41. INTERACTION OF ANTITUMOR AGENTS WITH ACTIVATED ONCOGENES
    LEONARD ERICKSON; Fiscal Year: 1991
    ..From these studies it is hoped that anti-tumor agents might be selected for use against specific oncogenes due to the ability of the particular anti-tumor agent to efficiently inactivate critical oncogenes in the tumor cell...
  42. PRIMARY BREAST CANCER THERAPY GROUP (NSABP)
    David Plotkin; Fiscal Year: 1980
    ..The Memorial Cancer Research Foundation of Southern California provides the mechanism, both fiduciary and logistical, for the accrual of patients into NSABP protocols through the resources provided by ONSC...
  43. Novel Therapies for Myeloma and Related Malignancies
    Todd Zimmerman; Fiscal Year: 2006
    ..care for multiple myeloma has remained relatively unchanged since the 1960's with the introduction of pulse melphalan and prednisone...
  44. PRIMARY BREAST CANCER THERAPY GROUP (NSABP)
    HARVEY LERNER; Fiscal Year: 1980
    ..This institution participates in these protocols. Finally, an aim of this proposal is to enhance the multidisciplinary approach of this institution in clinical trials...
  45. PRIMARY BREAST CANCER THERAPY GROUP--NSABP
    HARVEY LERNER; Fiscal Year: 1991
    ..Finally, the aim of this proposal is to enhance the multidisciplinary approach of this institution in these clinical trials...
  46. BIOLOGIC AND THERAPEUTIC RESEARCH IN MULTIPLE MYELOMA
    Bart Barlogie; Fiscal Year: 1992
    ..Laboratory research will be integrated with a clinical program using high dose melphalan and total body irradiation (supported by bone marrow transplantation) as a consolidation therapy after VAD-..
  47. PRIMARY BREAST CANCER THERAPY GROUP
    CARL SUTHERLAND; Fiscal Year: 1980
    ..Sutherland is active in designing this protocol. A final aim of this proposal is to use it as a mechanism to continue to stress the multidisciplinary treatment of cancer that has been the philosophy of Tulane University for many years...
  48. PRIMARY CANCER THERAPY GROUP
    JANET WOLTER; Fiscal Year: 1991
    ..placebo in Stage I estrogen receptor positive patients. The colon protocols include registration of patients with Duke's A and D tumors, and 3 drugs vs. BCG vs. surgery alone in patients with Duke's B and C disease...
  49. Immunoglobulin Light Chain Fibrillogenesis
    DAVID SELDIN; Fiscal Year: 2006
    ..We have pioneered aggressive treatment using intravenous melphalan and autologous stem cell rescue with promising results for AL amyloidosis, however less than half of the ..
  50. BIOCHEMICAL RESPONSES OF HYPOXIC CELLS TO CHEMOTHERAPY
    Katherine Kennedy; Fiscal Year: 1993
    ..DNA repair in EMT 6 mouse mammary tumor cells will be determined using alkaline elution techniques...
  51. MODULATION OF ANTITUMOR DRUG ACTION BY DNA REPAIR
    Raymond Meyn; Fiscal Year: 1990
    ..These would include: the bifunctional alkylating agents e.g., nitrogen mustard, melphalan, and 1,3-bis(2-chloroethyl)-1-nitrosourea; cis-diamminedichloroplatinum; and mitomycin-C...
  52. GRP78 AND HYPERSENSITIVITY TO DNA CROSS LINKING AGENTS
    CHARLES BELFI; Fiscal Year: 2004
    ..in p53, alkylguanine transferase or the mismatch repair protein, hMLH1, were sensitized to BCNU, cisplatin or melphalan. This is important, first, since it is known that in many cases, tumors bearing genetic mutations are resistant ..
  53. PRIMARY BREAST CANCER THERAPY GROUP (NSABP)
    STEVEN ECONOMOU; Fiscal Year: 1980
    ..Parvum. A primary breast cancer study is examining segmental vs. total mastectomy with and without radiation. A bowel adjuvant project is evaluating the effect of chemotherapy vs. immunoprophylaxis vs. surgery alone...
  54. Magnetic Targeted Delivery of TNF Alpha and Melphalan
    Yuhua Li; Fiscal Year: 2003
    ..carriers (MTCs) to deliver the highly potent therapeutic agents Tumor Necrosis Factor alpha (TNFalpha) and melphalan to solid tumors or organs...
  55. The Role of Drug Resistance in Regional Melanoma Therapy
    Elizabeth Grubbs; Fiscal Year: 2002
    ..a more rational approach to the treatment of extremity melanoma, our group has focused on better defining melphalan pharmacokinetics and its relationship to toxicity and outcome, as well as by defining the drug resistance ..
  56. DRUG-INDUCED SCES IN HUMAN PRIMARY TUMOR CELL CULTURE
    PHILIP TOFILON; Fiscal Year: 1991
    ..curves will be generated after treatment of primary cultures of human tumor cells with cis-platinum, BCNU or melphalan and the relative sensitivities as predicted by the SCE and a survival assay compared...
  57. Phase 3 stem cell transplant for light chain amyloidosis
    Morie A Gertz; Fiscal Year: 2011
    ..In addition, the analysis of clonal precursor B cells in the periphery and kinetics of amyloid formation of the monoclonal light chain will allow us to define and determine the mechanisms of disease progression and response to therapy. ..
  58. Phase II Trial of Thalidomide in Primary Amyloidosis
    Angela Dispenzieri; Fiscal Year: 2002
    ..The ultimate goal of the proposed studies is to improve the prognosis of patient with this fatal disease. ..
  59. Defibrotide for the treatment of severe hepatic veno-cc*
    Paul Richardson; Fiscal Year: 2007
    ..Abstract Not Provided ..